Cancer Commons aims to put the most up-to-date information about cancer treatment into the hands of patients. To keep this information current, Cancer Commons’ Chief Scientist Emma Shtivelman and collaborators periodically comb the scientific literature to compile and publish review papers that serve as “consensus models” of different cancer types and how they’re treated. A new consensus model was recently published for prostate cancer in the scientific journal Oncotarget.
The new consensus model describes the molecular underpinnings of prostate cancer, and how different genetic mutations and other molecular-scale changes are used to develop different treatments. The model serves as the scientific foundation of the personalized, patient-friendly information Cancer Commons provides to prostate cancer patients, and it will be updated as new insights emerge.